Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLink™ Database

被引：0
|
作者：
Hoogwerf, Byron J.
Pelletier, Elise M.
Smith, Daniel B.
Best, Jennie H.
机构：
[1] Lilly USA LLC, Indianapolis, IN USA
[2] IMS Hlth, Watertown, MA USA
[3] IMS Healthcare, Watertown, MA USA
[4] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
CIRCULATION | 2010年 / 122卷 / 21期
关键词：
Cardiovascular disease prevention; Type; 2; Diabetes; Glucose;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13242
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Initial glucose-lowering therapy and cardiovascular outcomes in type 2 diabetes
    Misnikova, I. V.
    Dreval, A. V.
    Kovaleva, Y. A.
    DIABETOLOGIA, 2012, 55 : S326 - S326
  • [32] The influence of glucose-lowering therapies on cancer specific mortality in type 2 diabetes
    Ioacara, S.
    Guja, C.
    Ionescu-Tirgoviste, C.
    Fica, S.
    Sabau, S.
    Radu, S.
    Anghel, M.
    Tiu, C.
    DIABETOLOGIA, 2011, 54 : S99 - S99
  • [33] Frailty in randomised controlled trials of glucose-lowering therapies for type 2 diabetes
    Wightman, H.
    Butterly, E.
    Wei, L.
    Mcchrystal, R.
    Sattar, N.
    Adler, A.
    Phillipo, D.
    Dias, S.
    Welton, N.
    Clegg, A.
    Witham, M.
    Rockwood, K.
    Mcallister, D.
    Hanlon, P.
    AGE AND AGEING, 2025, 54
  • [34] Use of New Glucose-Lowering Drugs and the Risk of Major Adverse Cardiovascular Events in People with Type 2 Diabetes and Prior Stroke
    Bae, Jae Hyun
    Choi, Jimi
    Kim, Nam Hoon
    Kim, Sin Gon
    DIABETES, 2023, 72
  • [35] Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany
    Rüdiger Göke
    Giovanni Bader
    Markus Dworak
    Diabetes Therapy, 2014, 5 : 183 - 191
  • [36] Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany
    Goeke, Ruediger
    Bader, Giovanni
    Dworak, Markus
    DIABETES THERAPY, 2014, 5 (01) : 183 - 191
  • [37] Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes
    Khunti, K.
    Bellary, S.
    Karamat, M. A.
    Patel, K.
    Patel, V.
    Jones, A.
    Gray, J.
    Shepherd, P.
    Hanif, W.
    DIABETIC MEDICINE, 2017, 34 (01) : 64 - 68
  • [38] INFLUENCE OF GLUCOSE-LOWERING STRATEGIES ON FRACTURE RISK IN TYPE 2 DIABETES
    Gusova, A. A.
    Pavlova, M. G.
    Melnitchenko, G. A.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S160 - S161
  • [39] Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents
    Anselmino, Matteo
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2009, 23 (06) : 427 - 433
  • [40] The risk of heart failure among patients receiving exenatide twice daily versus other glucose-lowering medications for diabetes: a matched retrospective analysis of the GE Healthcare EMR data
    Best, J. H.
    Maggs, D.
    Little, W.
    Chiquette, E.
    Saunders, W. B.
    DIABETOLOGIA, 2011, 54 : S326 - S326
12345